12:00 AM
Mar 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Transdur-Sufentanil: Phase IIb data

Data from an open-label, U.S. Phase IIb trial in 74 patients showed that 2 dose titration regimens for converting opioid-experienced patients to once-weekly Transdur-Sufentanil patch achieved the desired analgesic effect and side-effect profile. The company said the 2 dose...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >